The COVID-19 vaccine developed by Taiwan’s Medigen Vaccine Biologics Co has been available to the public since last week, based on an emergency use authorization by the Food and Drug Administration.
That it has been authorized before the completion of phase 3 clinical trials has sparked debate.
Those opposed to the vaccine’s early approval argue that not waiting for data from phase 3 clinical trials goes against medical ethics, as it leaves people without sufficient data about the vaccine’s full effects on their body.
To assess whether the approval process was safe, it is important to understand the scientific criteria for
April 26, 2021
Following a rise in xenophobia directed toward Asian Americans at the beginning of the COVID-19 pandemic, the past few months have seen a string of high-profile attacks that increased awareness of violence against members of the Asian American community.
Since the shutdown began over a year ago, nearly 3,800 Asian Americans have reported being victims of racist physical or verbal attacks, according to Stop AAPI Hate, a group formed last year to draw awareness to this issue.
To provide an opportunity for the community to come together and address the rise of anti-Asian hate crimes through conversation, the Hugh Downs School of Human Communication at Arizona State University held a Storyscope Project event, “Surviving Anti-Asian Racism During COVID-19.” The event was held via Zoom on April 17.